drugset / Trial / NCT07671534

Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

NCT07671534

Phase 2 Recruiting 60 enrolled Sarcoma Oncology Research Center, LLC
NaSingle-groupOpen-labelTreatment

Summary

This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.

Timeline

Start
2026-06
Primary completion
2029-06
Completion
2029-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 600 mg/m2 Intravenous
Subject Mitomycin C Other / unclassified 14 mg Intravenous
Subject Thalidomide Other / unclassified 100 mg Oral

Indications

No indication recorded.